- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01517022
Intensive Smoking-cessation Intervention Versus Smoking-cessation Advice in Smear-positive Patients With Pulmonary Tuberculosis
Impact of a Package of Intensive Smoking-cessation Interventions Versus Smoking-cessation Advice on Outcomes in Smear-positive Patients With Pulmonary Tuberculosis; a Randomised Controlled Trial (STB_RCT).
The aim of the study is to determine the impact of a package of smoking-cessation interventions on a composite measure of Tuberculosis (TB) treatment-related outcomes.
Given the lack of objective clinical data/evidence about the impact of smoking-cessation on TB-related outcomes, yet subjective expert opinion that smoking cessation is highly likely to be beneficial particularly in patients with TB, this study proposes to determine the impact of an intensive package of smoking-cessation interventions aimed to promote smoking-cessation (counseling plus nicotine replacement therapy, NRT), on patient response to anti-tuberculosis therapy. This is to be compared with the structured counselling for smoking-cessation that is recommended to be routinely provided by health care workers to all patients who are smokers. If the results prove that such a smoking-cessation PI indeed improves outcomes in TB patients, such information would strongly motivate for the institution of more intensive smoking-cessation interventions in TB clinics than is currently being employed for TB patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
New Delhi, India, 110029
- All India Institute of Medical Sciences, Ansari Nagar
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- any adult (> 18 years)
- Recently diagnosed (primary TB/Relapse TB) smear-positive TB patient who self-reports to smoke at least 10 whole cigarettes or bidis (rolled tobacco leaf) per day, every day
Exclusion Criteria:
patients will be excluded from recruitment to the study if they fall into any one or more of these exclusion categories:
- Inability to give consent or < 18 years
- Patients who self-report to smoke less than 10 whole cigarettes/bidis per day
- TB patients who have already started anti-tuberculosis therapy for more than 1 week.
- Patients with known multidrug-resistant TB (or XDR) (information provided by patient or the information is available in the clinic folder).
- Known HIV-positive patients
- Contra-indications to NRT (patients with a history of severe cardiovascular disease including arrhythmias, recent myocardial infarction (within the last 6 months), recent cerebrovascular incident (6 months), and/ or history of peripheral vascular disease, phaeochromocytoma, poorly controlled diabetes mellitus, hyperthyroidism, renal/hepatic impairment or gastritis/peptic ulcers). Patients with asthma or depression will also be excluded, as quitting may have an effect on medications used for these conditions. Patients with severe skin disorders (such as psoriasis or eczema) will also be excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control arm
Control arm patients will receive pre designed pamphlets and structured conselling for smoking cessation by trained counsellors along with routine DOTS treatment
|
|
Active Comparator: Intervention arm
Cessation arm patients will receive pre designed pamphlets and structured conselling for smoking cessation by trained counsellors along and nicotine replacement therapy(NRT) and routine DOTS treatment
|
nicotine replacement therapy 2mg for patients cessation arm for period of 6 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
1. Change in TB Score at second month and sixth month
Time Frame: Measured at baseline, second month and sixth month.
|
Composite score for objective and subjective improvement measured at baseline, second month and sixth month
|
Measured at baseline, second month and sixth month.
|
Sputum culture conversion
Time Frame: Measured at baseline and second month
|
Sputum culture conversion at second month using solid/liquid culture technique
|
Measured at baseline and second month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sputum smear conversion
Time Frame: Measured at baseline, second week, fourth week, second month and sixth months
|
Protocol was amended to access sputum conversion weekly up to second month
|
Measured at baseline, second week, fourth week, second month and sixth months
|
Mortality at sixth month
Time Frame: Sixth month
|
To determine number of mortality at the end of follow-up
|
Sixth month
|
More than 10% weight gain at six months
Time Frame: Sixth month
|
To determine rate of weight gain after completion of treatment
|
Sixth month
|
Proportion of subjects in each group that have quit smoking at second month
Time Frame: Sixth month
|
To determine the rate of smoking cessation in the cohort
|
Sixth month
|
Treatment completion
Time Frame: Six months for new cases and eight months for re-treatment cases following regimen 2
|
Six months for new cases and eight months for re-treatment cases following regimen 2
|
|
Cure, failure and default rate
Time Frame: At sixth month
|
To determine cure, failure and default rate in the cohort
|
At sixth month
|
Collaborators and Investigators
Investigators
- Principal Investigator: Surendra K Sharma, MD, Ph.D., AIIMS, New Delhi
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Lung Diseases
- Bacterial Infections
- Bacterial Infections and Mycoses
- Gram-Positive Bacterial Infections
- Actinomycetales Infections
- Mycobacterium Infections
- Tuberculosis
- Tuberculosis, Pulmonary
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Cholinergic Agents
- Ganglionic Stimulants
- Nicotinic Agonists
- Cholinergic Agonists
- Nicotine
Other Study ID Numbers
- SKS/Med/NI1161
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tuberculosis
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis InfectionUnited States
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis InfectionUnited States
-
University of Cape TownUniversity of Stellenbosch; University of Cape Town Lung Institute; University... and other collaboratorsCompletedTuberculosis | Multidrug Resistant Tuberculosis | Extensively-drug Resistant TuberculosisSouth Africa
-
Universiteit AntwerpenAurum Institute; University of Stellenbosch; University of the Free State; Free...RecruitingDrug-resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses | Multidrug Resistant TuberculosisSouth Africa
-
Assistance Publique - Hôpitaux de ParisCompletedExtrapulmonary Tuberculosis | Lymph Node Tuberculosis | Bone TuberculosisFrance
-
Centers for Disease Control and PreventionBoston University; Pfizer; Columbia University; University of Texas; University of... and other collaboratorsCompletedMulti-Drug Resistant Tuberculosis | Extensively Drug Resistant TuberculosisSouth Africa
-
University Medical Center GroningenCompletedMultidrug-resistant Tuberculosis | Extensively Drug-resistant TuberculosisNetherlands
-
Foundation for Innovative New Diagnostics, SwitzerlandInstitute of Tropical Medicine, Belgium; Research Center Borstel; National Institute...CompletedMultidrug-Resistant Tuberculosis | Isoniazid Resistant Pulmonary Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses
-
National Institute of Allergy and Infectious Diseases...CompletedPulmonary Tuberculosis | Multidrug Resistant Tuberculosis | Extensively Drug Resistant TuberculosisKorea, Republic of
-
Wits Health Consortium (Pty) LtdUniversity of Cape Town; Perinatal HIV Research Unit of the University of the... and other collaboratorsActive, not recruitingTuberculosis | Multi Drug Resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Extensively Drug-Resistant Tuberculosis | Pre-XDR-TBSouth Africa
Clinical Trials on nicotine replacement therapy
-
University of Kansas Medical CenterPatient-Centered Outcomes Research InstituteCompletedSmoking | Pulmonary Disease, Chronic Obstructive | Tobacco Use DisorderUnited States
-
NYU Langone HealthNational Cancer Institute (NCI)Recruiting
-
Centre for Addiction and Mental HealthCanadian Cancer Society (CCS)RecruitingSmoking Cessation | Tobacco Smoking | Substance Use Disorders | Nicotine Dependence | Nicotine Use DisorderCanada
-
Mark Vander WegIowa City VA Health Care SystemUnknownNicotine Dependence | Smokeless TobaccoUnited States
-
Rutgers, The State University of New JerseyCompleted
-
Fred Hutchinson Cancer CenterPalo Alto Veterans Institute for Research; Bedford Research Corporation, Inc.; Jefferson Center, Community Mental Health Clinic and other collaboratorsCompletedSmoking | Bipolar DisorderUnited States
-
University of VermontActive, not recruitingNicotine Addiction | Quitting Smoking | E-Cig UseUnited States
-
University of VermontCompletedTobacco Use DisorderUnited States
-
University of MonastirCompletedSmoking | Recurrence | Acute Coronary SyndromeTunisia
-
Johns Hopkins UniversityNational Cancer Institute (NCI); New York University; Colorado State University; Perinatal HIV Research Unit of the University of the WitswatersrandRecruitingSmoking Cessation | HIV | Comorbidities and Coexisting ConditionsSouth Africa